文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

智利大规模接种灭活SARS-CoV-2疫苗的效果评估

Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile.
PubMed 文献 · N Engl J Med · 2021-07-07
一句话结论智利全国前瞻性队列显示,全程接种灭活SARS-CoV-2疫苗对预防Covid-19重症、住院和死亡有效。

采用时变Cox比例风险模型,调整人口学和临床特征后,全程免疫对预防Covid-19的有效性为65.9%,对住院为87.5%,对ICU入住为90.3%,对Covid-19相关死亡为86.3%。结果表明该疫苗可有效预防Covid-19及其重症结局,与二期试验结果一致。

要点

  • 全程免疫(第二剂后≥14天)对Covid-19相关死亡的有效性为86.3%(95%CI 84.5–87.9)。
  • 全程免疫对ICU入住的有效性为90.3%(95%CI 89.1–91.4),对住院为87.5%(95%CI 86.7–88.2)。
  • 全程免疫对预防Covid-19的有效性为65.9%(95%CI 65.2–66.6)。
  • 部分免疫定义为第一剂后≥14天且未接种第二剂,全程免疫定义为第二剂后≥14天,有效性按此时点评估。

适用人群与场景

  • 智利全国公共医保系统参保者,年龄≥16岁,研究期间为2021年2月2日至5月1日。

诊断标准与关键阈值

  • 部分免疫:接种第一剂后≥14天且尚未接种第二剂。
  • 全程免疫:接种第二剂后≥14天。
  • 疫苗有效性基于时变Cox比例风险模型估计的风险比变化,调整人口学和临床特征。

处置流程与药物剂量

  • 原文未提及具体给药方案、剂量、途径、频次或目标值。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 全程免疫对预防Covid-19的有效性65.9%(95%CI 65.2–66.6)。
  • 全程免疫对预防住院的有效性87.5%(95%CI 86.7–88.2)。
  • 全程免疫对预防ICU入住的有效性90.3%(95%CI 89.1–91.4)。
  • 全程免疫对预防Covid-19相关死亡的有效性86.3%(95%CI 84.5–87.9)。

证据类型、等级与局限

  • 证据类型:前瞻性全国队列研究。
  • 局限:原文未明确列出局限;设计上为观察性研究,疫苗有效性为调整后估计值。

对床旁实践的改变

  • 支持在急诊/ICU场景中,对符合条件人群按国家免疫规划完成灭活SARS-CoV-2疫苗全程接种,以降低Covid-19住院、ICU入住和死亡风险。
  • 对仅接种第一剂后≥14天但未完成第二剂者,不应视为全程免疫。
  • 原文未提及对已接种疫苗者急诊/ICU分诊、防护或治疗流程的具体改变。

指南或共识出处

  • 原文未提及指南或共识名称;研究由Agencia Nacional de Investigación y Desarrollo等资助。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Mass vaccination campaigns to prevent coronavirus disease 2019 (Covid-19) are occurring in many countries; estimates of vaccine effectiveness are urgently needed to support decision making. A countrywide mass vaccination campaign with the use of an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine (CoronaVac) was conducted in Chile starting on February 2, 2021.

METHODS: We used a prospective national cohort, including participants 16 years of age or older who were affiliated with the public national health care system, to assess the effectiveness of the inactivated SARS-CoV-2 vaccine with regard to preventing Covid-19 and related hospitalization, admission to the intensive care unit (ICU), and death. We estimated hazard ratios using the extension of the Cox proportional-hazards model, accounting for time-varying vaccination status. We estimated the change in the hazard ratio associated with partial immunization (≥14 days after receipt of the first dose and before receipt of the second dose) and full immunization (≥14 days after receipt of the second dose). Vaccine effectiveness was estimated with adjustment for individual demographic and clinical characteristics.

RESULTS: The study was conducted from February 2 through May 1, 2021, and the cohort included approximately 10.2 million persons. Among persons who were fully immunized, the adjusted vaccine effectiveness was 65.9% (95% confidence interval [CI], 65.2 to 66.6) for the prevention of Covid-19 and 87.5% (95% CI, 86.7 to 88.2) for the prevention of hospitalization, 90.3% (95% CI, 89.1 to 91.4) for the prevention of ICU admission, and 86.3% (95% CI, 84.5 to 87.9) for the prevention of Covid-19-related death.

CONCLUSIONS: Our results suggest that the inactivated SARS-CoV-2 vaccine effectively prevented Covid-19, including severe disease and death, a finding that is consistent with results of phase 2 trials of the vaccine. (Funded by Agencia Nacional de Investigación y Desarrollo and others.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Jara A, Undurraga EA, González C, et al. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. N Engl J Med. 2021. PMID: 34233097. doi:10.1056/NEJMoa2107715

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。